(Q51013825)

27 March 2018

title

Antiangiogenic ruthenium(ii) benzimidazole complexes, structure-based activation of distinct signaling pathways. (English)

1 reference

27 March 2018

1 reference

angiogenesis inhibitor

1 reference

Haoqiang Lai

1

1 reference

27 March 2018

Zhennan Zhao

2

1 reference

27 March 2018

Linlin Li

3

1 reference

27 March 2018

Wenjie Zheng

4

1 reference

27 March 2018

Tianfeng Chen

5

1 reference

27 March 2018

publication date

1 March 2015

1 reference

27 March 2018

published in

Metallomics

1 reference

27 March 2018

volume

7

1 reference

27 March 2018

issue

3

1 reference

27 March 2018

page(s)

439-447

1 reference

27 March 2018

Tumor angiogenesis: molecular pathways and therapeutic targets

cites work

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Molecular mechanisms and clinical applications of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Vascular endothelial growth factor signaling pathways: therapeutic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Antiangiogenic strategies for treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Pathophysiological consequences of VEGF-induced vascular permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

On the biological properties of alkynyl phosphine gold(I) complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Naphthalimide gold(I) phosphine complexes as anticancer metallodrugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

A gold(I) phosphine complex containing a naphthalimide ligand functions as a TrxR inhibiting antiproliferative agent and angiogenesis inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Modulation of the biological properties of aspirin by formation of a bioorganometallic derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Organometallic ruthenium(II) arene compounds with antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

A binuclear gold(I) complex with mixed bridging diphosphine and bis(N-heterocyclic carbene) ligands shows favorable thiol reactivity and inhibits tumor growth and angiogenesis in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Ruthenium polypyridyl complexes that induce mitochondria-mediated apoptosis in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Ruthenium complexes containing 2,6-bis(benzimidazolyl)pyridine derivatives induce cancer cell apoptosis by triggering DNA damage-mediated p53 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Characterization of a ruthenium(III)/NAMI-A adduct with bovine serum albumin that exhibits a high anti-metastatic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Discovery of a highly tumor-selective organometallic ruthenium(II)-arene complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Interaction between 8-hydroxyquinoline ruthenium(II) complexes and basic fibroblast growth factors (bFGF): inhibiting angiogenesis and tumor growth through ERK and AKT signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Ruthenium complexes containing bis-benzimidazole derivatives as a new class of apoptosis inducers

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Imidazole and benzimidazole derivatives as chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Synthesis, characterization, photophysical, and anion-binding studies of luminescent heteroleptic bis-tridentate ruthenium(II) complexes based on 2,6-bis(benzimidazole-2-yl)pyridine and 4'-substituted 2,2':6',2'' terpyridine derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Synthesis, structural characterization, and photophysical, spectroelectrochemical, and anion-sensing studies of heteroleptic ruthenium(II) complexes derived from 4'-polyaromatic-substituted terpyridine derivatives and 2,6-bis(benzimidazol-2-yl)pyrid

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

On the antitumor properties of novel cyclometalated benzimidazole Ru(II), Ir(III) and Rh(III) complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

EPOX inhibits angiogenesis by degradation of Mcl-1 through ERK inactivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Microwave-assisted synthesis of arene ruthenium(II) complexes that induce S-phase arrest in cancer cells by DNA damage-mediated p53 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Mixed-ligand ruthenium polypyridyl complexes as apoptosis inducers in cancer cells, the cellular translocation and the important role of ROS-mediated signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Molecular and cellular characterization of the biological effects of ruthenium(II) complexes incorporating 2-pyridyl-2-pyrimidine-4-carboxylic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Enhancement of cell permeabilization apoptosis-inducing activity of selenium nanoparticles by ATP surface decoration

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Caspase- and p53-dependent apoptosis in breast carcinoma cells induced by a synthetic selenadiazole derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Ruthenium polypyridyl complexes as inducer of ROS-mediated apoptosis in cancer cells by targeting thioredoxin reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Selenocystine potentiates cancer cell apoptosis induced by 5-fluorouracil by triggering reactive oxygen species-mediated DNA damage and inactivation of the ERK pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

Synthesis of 2-Pyridyl-benzimidazole Iridium(III), Ruthenium(II), and Platinum(II) Complexes. Study of the Activity as Inhibitors of Amyloid-β Aggregation and Neurotoxicity Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC4MT00312H

21 January 2018

Identifiers

DOI

10.1039/C4MT00312H

1 reference

27 March 2018

PubMed ID

25630534

1 reference

27 March 2018